Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Inaki Alvarez"'
Autor:
Alejandro Tres, Albert B. De Leo, Maria D. Garcia-Prats, Miguel Ángel Burillo, Andreas E. Albers, Javier Sanz, Jose I. Mayordomo, Manuel Moros, María del Carmen Visus, Inaki Alvarez-Busto, Antonio Güemes
Publikováno v:
Medicina Clínica. 131:685-688
Fundamento y objetivo: La proteina p53 esta sobreexpresada en la mitad de los tumores humanos. Se ha descrito que se produce una respuesta inmunologica especifica mediada por linfocitos T citotoxicos dirigidos contra el epitopo 264-272 de p53 en paci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7090143db4f558275c79f3799ef3687f
https://doi.org/10.1157/13129112
https://doi.org/10.1157/13129112
Autor:
Iñaki Álvarez, Adrián Tirado-Herranz, Belén Alvarez-Palomo, Jordi Requena Osete, Michael J. Edel
Publikováno v:
Cells, Vol 12, Iss 24, p 2800 (2023)
Background: Proteins targeted by the ubiquitin proteasome system (UPS) are identified for degradation by the proteasome, which has been implicated in the development of neurodegenerative diseases. Major histocompatibility complex (MHC) molecules pres
Externí odkaz:
https://doaj.org/article/875d4facc8024f988990703a5870360c
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/f03a5a7b597e4a35a98b5e8f54a1ec72
Autor:
Inaki, Alvarez-Busto, Luis, Martinez-Moya, Rodrigo, Lastra, Javier, Alcedo, Damaris, Quiles, Antonio, Lobo-Escolar, Carlos, Vazquez, Miguel, Burillo, Carla, Toyas-Miazza, Rosario, Ortas-Nadal
Publikováno v:
The New Zealand medical journal. 120(1262)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b0bb1b54ef8c85a6bb4544a644b4179
https://pubmed.ncbi.nlm.nih.gov/17891214
https://pubmed.ncbi.nlm.nih.gov/17891214
Autor:
Luis Manso, Cristina Hernando, María Galán, Mafalda Oliveira, Miguel A. Cabrera, Raquel Bratos, César A. Rodríguez, Manuel Ruiz-Borrego, Salvador Blanch, Antonio Llombart-Cussac, Juan I. Delgado-Mingorance, Iñaki Álvarez-Busto, Isabel Gallegos, Lucía González-Cortijo, Serafín Morales, Elena Aguirre, Blanca A. Hernando, Ana Ballesteros, José E. Alés-Martínez, Cristina Reboredo, Amparo Oltra, María González-Cao, Marta Santisteban, Diego Malón, Isabel Echeverría, Elisa García-Garre, Estela Vega, Sònia Servitja, Raquel Andrés, Carlos E. Robles, Rafael López, Elena Galve, María J. Echarri, Marta Legeren, Fernando Moreno
Publikováno v:
Breast, Vol 54, Iss , Pp 286-292 (2020)
Background: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during
Externí odkaz:
https://doaj.org/article/79a375e0252b436e8ea177a9f4f57a3e
Autor:
Isabel Gallegos Sancho, Maria Dolores Torregrosa, Javier Cassinello, Andrés García-Palomo, Cristina Llorca, M. Mendez, Ramon Perez-Carrion, Gustavo Catalan, Esperanza J. Carcache de Blanco, Rosa Llorente, Antonia Perelló, Maria Jose Garcia Lopez, Coralia Bueno, Antonio J. Fernández, Xabier Mielgo Rubio, Elena Galve Calvo, Luis Manso, Jose Ignacio Chacon, Hernán Cortés-Funes, Inaki Alvarez
Publikováno v:
Web of Science
e12020 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites, location of metastases and patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53b99ac310f7bef761d692841f6c02f5
https://doi.org/10.1200/jco.2013.31.15_suppl.e12020
https://doi.org/10.1200/jco.2013.31.15_suppl.e12020
Autor:
Javier Cassinello, Maria Jose Garcia Lopez, Santos Enrech, Blanca Hernando, Maria Dolores Torregrosa, Elena Galve Calvo, Esperanza J. Carcache de Blanco, Isabel Gallegos Sancho, Gustavo Catalan, Andres Garcia Palomo, Cristina Llorca, Hernán Cortés-Funes, Ramon Perez-Carrion, Inaki Alvarez, Xabier Mielgo Rubio, Rosa Llorente, Mauro Oruezabal, Luis Manso, Miguel Angel Lara, Jose Ignacio Chacon Lopez-Muniz
Publikováno v:
Journal of Clinical Oncology. 30:e11074-e11074
e11074 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites and location of metastases and patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88b2074c4e896ddaf45b694dc0c164d
https://doi.org/10.1200/jco.2012.30.15_suppl.e11074
https://doi.org/10.1200/jco.2012.30.15_suppl.e11074
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Erika Margaret Scholz, Miguel Marcilla, Xavier Daura, David Arribas-Layton, Eddie A. James, Iñaki Alvarez
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined in 1994 based o
Externí odkaz:
https://doaj.org/article/57848a499f4a4942966a9254dc1a4bf5